Research-Grade Peptides | 99%+ Purity Verified | US Delivery 2–5 Days
Save 5% with Crypto
SaiyanMed

Your Cart

No products in the cart.

What Is Thymosin Alpha-1 | Thymic Peptide for Immune Signaling Research

Research Use Only Notice: This article discusses Thymosin Alpha-1 only as a laboratory research reagent. The information below is intended for qualified researchers carrying out controlled in-vitro experiments or approved laboratory animal studies.

It is not intended for personal, household, human, veterinary, diagnostic, cosmetic, or other non-research use.

Thymosin Alpha-1, usually shortened to Tα1, is a peptide made of 28 amino acids. It was first isolated from thymosin fraction 5, a mixture prepared from calf thymus tissue.

A 1977 paper reported its amino-acid sequence and described it as a highly acidic peptide.[1]

What Is Thymosin Alpha-1

The native peptide starts with an acetylated serine and has the sequence Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN. Tα1 corresponds to residues 1-28 of prothymosin alpha.

Laboratory research has also shown that a lysosomal asparaginyl endopeptidase (legumain) can release Tα1 from prothymosin alpha by cleaving at the Asn28-Gly29 bond under controlled experimental conditions.[3]

Basic Information

Property Reference Information
Common name Thymosin Alpha-1; Tα1
Database name Thymalfasin
Sequence Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN
Number of residues 28 amino acids
Molecular formula C129H215N33O55
Average molecular weight Approximately 3,108.3 g/mol. The average molecular weight used for concentration conversion should not be directly compared with a monoisotopic m/z value. Mass-spectrometry acceptance criteria should specify the theoretical mass convention, charge state, expected adducts and deconvolution method.
CAS numbers listed by PubChem 62304-98-7 and 69521-94-4. PubChem associates both numbers with thymalfasin-related records, but database qualifiers and registry sources differ. The applicable identifier should be confirmed together with the full sequence, terminal modifications and measured molecular mass.
N-terminal group Acetylated serine
C-terminal group Free carboxylic acid
Acidic residues 3 aspartate residues and 6 glutamate residues
Basic residues 4 lysine residues
General charge near neutral pH Strongly negative. The sequence contains three aspartate residues, six glutamate residues and four lysine residues. Together with its acetylated N-terminus and free C-terminus, this gives Tα1 a strong net negative charge near neutral pH.

PubChem lists the sequence, formula, average molecular weight and both CAS numbers shown above.[2] A batch should not be identified by CAS number alone.

The sequence, terminal groups and measured molecular mass should also be checked.

Mass-spectrometry studies of recombinant Tα1 have reported an observed mass consistent with N-terminally acetylated Tα1 (approximately 3,108.79 Da). The same work used reverse-phase HPLC and tandem mass spectrometry together to compare recombinant and chemically synthesised material.[4]

What Laboratory Studies Show

The laboratory studies summarised below mainly examine dendritic cells, Toll-like-receptor-related pathways and associated immune-signaling markers. These results come from cell cultures and laboratory animal models.

They should not be treated as evidence of an effect outside the tested model.

In a 2004 study, Tα1 was tested in fungus-exposed dendritic cells and in a mouse model. In the cell experiments, the researchers linked the observed dendritic-cell response to a MyD88-dependent Toll-like receptor pathway and to the cell-signaling proteins p38 MAPK and NF-κB.

The study also reported changes in interleukin-12 production.[5]

A separate dendritic-cell study reported that Tα1 increased the activity of indoleamine 2,3-dioxygenase (IDO) in the tested mouse cells. In that model, the response required TLR9 and type I interferon receptor signaling.[6]

A 2015 in-vitro study tested Tα1 in primary monocyte-derived dendritic cells exposed to different Toll-like receptor stimuli. The results changed with the type of stimulus.

Some markers increased when the cells were exposed to viral-pattern TLR3 or TLR7/8 stimuli, while several measured responses decreased under the bacterial-pattern TLR2 or TLR4 conditions used in the study.[7]

These studies show that the response to Tα1 can depend on the cell type, species, stimulus, concentration and test method. They do not show that Tα1 always increases immune signaling.

They also do not, by themselves, prove that Tα1 directly binds physically to TLR2 or TLR9. It is more accurate to say that certain TLR-related pathways were involved in the reported experiments.[5][6][7]

Common Research Setups

The examples below are general study-design ideas. They are not universal protocols, and each laboratory must set its own controls and acceptance rules.

  • TLR pathway studies: Compare Tα1-treated cells with a vehicle control, a suitable positive control and, where possible, a receptor blocker or pathway-deficient model. Cytokine changes alone are not enough to prove direct receptor binding.
  • Dendritic-cell studies: Common measurements may include MHC or HLA markers, CD40, CD80, CD86 and selected cytokines. The cell source, culture method, exposure time and co-stimulus should always be reported.
  • IDO studies: Possible measurements include IDO expression, tryptophan levels, kynurenine levels and related signaling markers. TLR9 and type I interferon pathway controls are needed before claiming that these pathways are required.
  • Co-stimulation studies: Include a vehicle group, a Tα1-only group, a co-stimulus-only group and a combined group. This makes it possible to tell whether the combined response is higher, lower or unchanged.

Every report should state the species or cell source, concentration, exposure time, number of repeats, controls and statistical method. Findings from one model should not automatically be applied to another model.

Laboratory Concentration Conversion

The following conversions use an average molecular weight of 3,108.3 g/mol.[2]

Concentration in µM = concentration in µg/mL × 1,000 ÷ 3,108.3

Concentration in nM = concentration in ng/mL × 1,000 ÷ 3,108.3

Mass Concentration Approximate Molar Concentration
10 ng/mL 3.22 nM
100 ng/mL 32.2 nM
1 µg/mL 0.322 µM
10 µg/mL 3.22 µM
100 µg/mL 32.2 µM

These values are laboratory concentration conversions only. They are not recommended working concentrations or administration amounts.

The concentration used in an experiment should be chosen from relevant published methods and then checked in the laboratory’s own assay.

If the certificate of analysis gives a net peptide-content value, that value should be considered when preparing quantitative solutions. The total weight of lyophilized powder may also include water, counterions or other non-peptide material.

The required powder mass for a given target peptide mass can be calculated as:

Required powder mass = target peptide mass ÷ net peptide-content fraction

For example, if the net peptide content is 0.80 and the target is 1.00 mg of peptide, the theoretical required powder mass is 1.25 mg. This calculation is valid only when the COA defines the “peptide content” reporting basis clearly; HPLC main-peak area alone should not be substituted for this fraction.

Laboratory Handling

Solubility: A fixed statement such as “Tα1 is always soluble at 1-5 mg/mL” should not be used. Actual solubility can change with the batch, counterion, concentration, pH, buffer, salt level and temperature.

Before preparing a full stock, test a small amount in the selected laboratory-grade water or assay buffer. Check for visible particles, cloudiness or precipitation.

A clear solution does not prove that the peptide is chemically unchanged, so appearance should not replace analytical testing.

Lyophilised storage: Follow the temperature and storage period stated in the batch-specific certificate of analysis or stability documents. When no product-specific instruction is available, a common research-laboratory default is to keep lyophilised peptide dry, protected from light and stored at approximately -20 °C.

This is a general handling practice and not proof of a specific shelf life.

Allow a cold, sealed container to reach room temperature before opening it. This helps reduce moisture condensation inside the container.

After dissolution: Do not claim a fixed storage time for a reconstituted Tα1 solution unless it is supported by formulation-specific stability data. Peptide stability in water can change with pH, buffer type, temperature, concentration and exposure to oxygen or light.[12]

For laboratory work, prepare small aliquots under validated conditions and avoid unnecessary freeze-thaw cycles or long storage at room temperature. Working solutions should be prepared fresh when the assay is sensitive to small changes in peptide quality.

How to Read a COA

A certificate of analysis, or COA, describes the test results for a specific batch. It does not prove that the material is suitable for every research method, and it does not establish safety or effectiveness for any non-research use.

COA Test What It Can Show What It Does Not Show by Itself
HPLC purity The relative integrated peak areas detected under the stated chromatographic and detection conditions Full sequence identity, exact molecular mass, net peptide content, water content, endotoxin or sterility
Intact mass spectrometry Whether the measured intact mass is consistent with the expected molecular composition under the stated ionisation, charge-state, adduct and deconvolution conditions Unique amino-acid sequence identity, modification localisation, stereochemical identity, complete purity, water, residual solvents, endotoxin or sterility
MS/MS Can provide stronger evidence for sequence identity and terminal modifications when adequate fragment-ion coverage and modification-localising ions are obtained The amount of every possible impurity
Water test The amount of moisture measured by the stated method Peptide identity or chromatographic purity
Residual-solvent test The amount of selected volatile solvents Sequence identity, peptide content or endotoxin
Endotoxin test The measured level of bacterial endotoxin under the stated method Sterility, peptide identity or general purity

HPLC purity and peptide content are not the same measurement.

An HPLC area percentage reports the relative peak areas seen under one method. It should not automatically be treated as the percentage of active peptide in the total powder weight.

HPLC retention time alone is also not a strong enough identity test. FDA guidance states that a single chromatographic retention time is not specific enough when closely related compounds may be present.

Combining HPLC with mass spectrometry or another suitable test gives stronger identity evidence.[10]

ICH Q2(R2) explains that an analytical method should be suitable for its intended purpose. It also recommends using another supporting method when one method does not provide enough selectivity.[8]

A historical FDA inspection reference document notes that no single identity test may be sufficient in every case and lists HPLC, amino-acid sequencing, peptide mapping and mass spectrometry as different tools that may be used when checking identity and quality. It is used here only to illustrate the general principle of orthogonal identity confirmation.[9]

Residual solvents should be tested separately with a suitable method when they may be present from manufacturing. The current ICH Q3C(R9) guideline provides a recognised framework for the classification, assessment and control of residual solvents in pharmaceutical materials.[11]

Endotoxin is especially important in TLR, dendritic-cell and cytokine experiments because endotoxin contamination can change the same types of readouts being studied.

High HPLC purity does not mean that a sample has low endotoxin.

The FDA and ICH documents cited here are used only to explain general analytical principles. Their inclusion does not mean that a research-grade peptide has been produced or tested as a pharmaceutical product.

Limits of the Evidence

The biological findings described in this article come from in-vitro cell studies or controlled laboratory animal models. Results can change with the species, cell type, peptide batch, concentration, exposure time, co-stimulus and measurement method.

Changes in cytokines, receptors, enzymes or cell-surface markers do not by themselves prove a wider biological benefit. A research batch meeting its stated HPLC or mass-spectrometry specification also does not establish human or veterinary safety, clinical effectiveness, sterility or approval for any non-research use.

References

  1. Goldstein AL, Low TLK, McAdoo M, et al. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci USA. 1977;74(2):725-729.
    PubMed 265536.
  2. National Center for Biotechnology Information. PubChem Compound Summary for Thymalfasin, CID 16130571 (C129H215N33O55, 3,108.3 g/mol, CAS 62304-98-7 / 69521-94-4).
    PubChem.
  3. Sarandeses CS, Covelo G, Diaz-Jullien C, Freire M. Prothymosin alpha is processed to thymosin alpha 1 and thymosin alpha 11 by a lysosomal asparaginyl endopeptidase. J Biol Chem. 2003;278(15):13286-13293. doi:10.1074/jbc.M213005200.
    PubMed 12554742.
  4. Liu B, Gong X, Chang S, Sun P, Wu J. Generation of mature N-alpha-terminal acetylated thymosin alpha1 by cleavage of recombinant prothymosin alpha. ScientificWorldJournal. 2013;2013:387282. doi:10.1155/2013/387282.
    PMC3830889.
  5. Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signaling. Blood. 2004;103(11):4232-4239.
    PubMed 14982877.
  6. Romani L, Bistoni F, Perruccio K, et al. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood. 2006;108(7):2265-2274.
    PubMed 16741252.
  7. Giacomini E, Severa M, Cruciani M, et al. Dual effect of Thymosin Alpha-1 on primary monocyte-derived dendritic cells stimulated in vitro with viral and bacterial Toll-like receptor agonists. Expert Opin Biol Ther. 2015;15(Suppl 1):S59-S70.
    PubMed 26096650.
  8. International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures. Final version, November 2023.
    ICH Q2(R2).
  9. U.S. Food and Drug Administration. Biotechnology Inspection Guide (1991).
    FDA Biotechnology Inspection Guide.
  10. U.S. Food and Drug Administration. Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products.
    FDA Q6A.
  11. International Council for Harmonisation. ICH Q3C(R9): Impurities – Guideline for Residual Solvents. Current Step 4 version, January 2024.
    ICH Q3C(R9).
  12. Nugrahadi PP, Hinrichs WLJ, Frijlink HW, Schoneich C, Avanti C. Designing formulation strategies for enhanced stability of therapeutic peptides in aqueous solutions: a review. Pharmaceutics. 2023;15(3):935.
    PubMed 36986796.

Research Use Only Disclaimer

Research Use Only: The T-alpha-1 product described on this page is supplied for laboratory research use only and is not intended for human or veterinary use. This article is provided for informational context regarding published laboratory research and general analytical and handling considerations, and does not constitute medical, clinical, veterinary guidance or treatment advice.